FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 356:1905-1908 May 10, 2007 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Audio Interview Perspective Perspective by The FUTURE II Study Group Perspective by Garland, S. M. Editorial by Baden, L. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The FUTURE II Study Group Related Article by Garland, S. M. PubMed Citation

Cancer prevention has fallen victim to the culture wars. Throughout the United States, state legislatures are scrambling to respond to the availability of Merck's human papillomavirus (HPV) vaccine, Gardasil, and to the likely introduction of GlaxoSmithKline's not-yet-approved HPV vaccine, Cervarix, which have been shown to be effective in preventing infection with HPV strains that cause about 70% of cases of cervical cancer. At the Centers for Disease Control and Prevention (CDC), the Advisory Committee on Immunization Practices (ACIP) has voted unanimously to recommend that girls 11 and 12 years of age receive the vaccine, and the CDC has added Gardasil . . . [Full Text of this Article]

Source Information

Professor Charo is a professor of law and bioethics at the University of Wisconsin, Madison.

An interview with Professor Charo can be heard at www.nejm.org.

This article has been cited by other articles:

• Balog, J. E. (2009). The Moral Justification for a Compulsory Human Papillomavirus Vaccination Program. AJPH 99: 616-622 [Abstract] [Full Text]  
• Edelstein, Z. R., Madeleine, M. M., Hughes, J. P., Johnson, L. G., Schwartz, S. M., Galloway, D. A., Carter, J. J., Koutsky, L. A. (2009). Age of Diagnosis of Squamous Cell Cervical Carcinoma and Early Sexual Experience. Cancer Epidemiol. Biomarkers Prev. 18: 1070-1076 [Abstract] [Full Text]  
• Hutchinson, D. J., Klein, K. C. (2008). Human papillomavirus disease and vaccines. Am J Health Syst Pharm 65: 2105-2112 [Abstract] [Full Text]  
• Bennett, M. P. (2008). Ethics and the HPV Vaccine: Considerations for School Nurses. The Journal of School Nursing 24: 275-283 [Abstract] [Full Text]  
• Opel, D. J., Diekema, D. S., Marcuse, E. K. (2008). A Critique of Criteria for Evaluating Vaccines for Inclusion in Mandatory School Immunization Programs. Pediatrics 122: e504-e510 [Abstract] [Full Text]  
• Outterson, K., Kesselheim, A. S. (2008). Market-Based Licensing For HPV Vaccines In Developing Countries. Health Aff (Millwood) 27: 130-139 [Abstract] [Full Text]  
• Lo, B. (2007). Human papillomavirus vaccination programmes. BMJ 335: 357-358 [Full Text]  
• Fimbres, A., Barton, L. L. (2007). How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?. AAP Grand Rounds 18: 16-17 [Full Text]  
• Stange, K. C. (2007). In This Issue: Clinical Diagnosis and Management. Ann Fam Med 5: 290-291 [Full Text]  
• Baden, L. R., Curfman, G. D., Morrissey, S., Drazen, J. M. (2007). Human Papillomavirus Vaccine -- Opportunity and Challenge. NEJM 356: 1990-1991 [Full Text]  
• (2007). HPV Vaccination: Data at Last. JWatch General 2007: 1-1 [Full Text]